EUVIMEDSkopri EUVIMED
Crossref

Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients

Garyn Metoyer iD, Harriz Z Whiteson iD, Yusi Chen iD, Yiting Li iD, Chenxi Gao iD, Gayathri Menon iD, Sunjae Bae iD, Krista L Lentine iD, Dorry L Segev iD, Mara A McAdams-DeMarco iD, Babak J Orandi iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70354 ↗

At a glance

Journal article in Clinical Transplantation, 2025. Written by Garyn Metoyer and 10 co-authors. Institution: NYU Langone Department of Surgery, New York, New York, USA. Major MEDLINE topics: Kidney Transplantation, Glucagon-Like Peptide-1 Receptor Agonists, Postoperative Complications, Hypoglycemic Agents. Cited 6 times so far (Crossref); 30 references. Funded by: NIDDK NIH HHS, National Institute of Allergy and Infectious Diseases, Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP1RA) provide survival benefits in people with diabetes, including kidney transplant (KT) recipients with pre‐existing diabetes. Post‐transplant diabetes mellitus (PTDM) is common, but the benefits of GLP1RAs remain undefined in this population. We aim to describe current usage practices and outcomes in PTDM.

Methods

We used USRDS and Medicare claims data (2013–2022) to conduct a drug utilization profile of GLP1RA among 7681 first‐time adult KT recipients with PTDM. We used survival analysis to estimate GLP1RA initiation incidence and associated patient, graft, and safety outcomes.

Results

A total of 430 adult KT recipients with PTDM were prescribed GLP1RA. Dulaglutide was the most commonly prescribed medication (46.1%). The 5‐year cumulative incidence of GLP‐1 receptor agonists prescription was 9.8%. Median (interquartile range) time from PTDM diagnosis to first prescription was 1.7 (0.6, 3.4) years. GLP1RA use was not associated with a difference in the risk of mortality or graft failure but was associated with a 1.80‐fold (95% confidence interval [CI]: 1.11–2.91) increased risk of diabetic retinopathy. No increased risk of pancreatitis, biliary complications, or medullary thyroid cancer were identified.

Conclusions

GLP1RA use in KT recipients with PTDM was not associated with graft or patient survival, though longer follow‐up is necessary. GLP1RA use was associated with an increased risk of diabetic retinopathy, and care should be taken when initiating these agents.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationGlucagon-Like Peptide-1 Receptor AgonistsPostoperative ComplicationsHypoglycemic AgentsDiabetes MellitusGraft RejectionKidney Failure, ChronicHumansMaleFemaleMiddle AgedGraft SurvivalFollow-Up StudiesPrognosisRisk FactorsSurvival RateAgedAdultRetrospective StudiesIncidenceTransplant RecipientsRecombinant Fusion ProteinsGlomerular Filtration RateKidney Function TestsUnited States

Author keywords

GLP1RAGLP‐1 receptor agonistkidney transplantpost‐transplant diabetes mellitussafetyutilization

Substances

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsRecombinant Fusion Proteins

Authors and institutions

  • NYU Langone Department of Surgery, New York, New York, USA.
  • Saint Louis University Department of Medicine, St. Louis, Missouri, USA.
  • NYU Langone Department of Population Health, New York, New York, USA.
  • NYU Langone Department of Medicine, New York, New York, USA.

ORCID profiles: Garyn Metoyer, Harriz Z Whiteson, Yusi Chen, Yiting Li, Chenxi Gao, Gayathri Menon, Sunjae Bae, Krista L Lentine, Dorry L Segev, Mara A McAdams-DeMarco, Babak J Orandi

Funding

  • NIDDK NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Metoyer, G., Whiteson, H. Z., Chen, Y., Li, Y., Gao, C., Menon, G., Bae, S., Lentine, K. L., Segev, D. L., McAdams-DeMarco, M. A., & Orandi, B. J. (2025). Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients. Clinical Transplantation. https://doi.org/10.1111/ctr.70354

Vancouver

Metoyer G, Whiteson HZ, Chen Y, Li Y, Gao C, Menon G, et al. Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients. Clinical Transplantation. 2025. doi:10.1111/ctr.70354

BibTeX
@article{Metoyer2025,
  author = {Metoyer, Garyn and Whiteson, Harriz Z and Chen, Yusi and Li, Yiting and Gao, Chenxi and Menon, Gayathri and Bae, Sunjae and Lentine, Krista L and Segev, Dorry L and McAdams-DeMarco, Mara A and Orandi, Babak J},
  title = {Utilization and Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists in Posttransplant Diabetes Mellitus in Kidney Transplant Recipients},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70354}
}
Start for free →